Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
511 results
Cited 38 times since 1992 (1.2 per year) source: EuropePMC
Clinical chemistry, Volume 38, Issue 4, 1 1 1992, Pages 534-540 Improved diagnosis of carcinoid tumors by measurement of platelet serotonin. Kema IP, de Vries EG, Schellings AM, Postmus PE, Muskiet FA
Carcinoid patients are diagnosed biochemically on the basis of increased urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA); urinary and platelet serotonin concentrations are considered to provide complementary information. Using established HPLC methods with fluorometric detection, we evaluated the clinical usefulness of measurements of urinary 5-HIAA and urinary, plasma, and platelet serotonin in 30 consecutive patients with histologically proven carcinoid tumors of fore-, mid-, and hind... Abstract
Cited 21 times since 1992 (0.7 per year) source: EuropePMC
British journal of cancer, Volume 65, Issue 3, 1 1 1992, Pages 405-408 A phase II study of high dose epirubicin in unresectable non small cell lung cancer. Smit EF, Berendsen HH, Piers DA, Smeets J, Riva A, Postmus PE
Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower cardiac and systemic toxicity. Recently, the maximum tolerated dose of this drug has been revised upwards with reported increased response rates in several malignancies. We initiated a phase II study of high-dose EPI as initial treatment for patients with advanced non-small cell lung cancer (NSCLC) (stage III and IV). Between May 1988 and November 1989, 25 patients were entered. The starting dose o... Abstract
Cited 2 times since 1992 (0.1 per year) source: EuropePMC
Chest, Volume 101, Issue 2, 1 1 1992, Pages 553-554 An asymptomatic hilar mass. Mannes GP, van der Jagt EJ, Postmus PE
Cited 6 times since 1992 (0.2 per year) source: EuropePMC
Seminars in oncology, Volume 19, Issue 1 Suppl 2, 1 1 1992, Pages 17-23 Second-line carboplatin-based chemotherapy for small cell lung cancer: the Groningen experience. Postmus PE, Smit EF, Berendsen HH, Haaxma-Reiche H
In this report, the results of two phase II studies and one pilot study of second-line carboplatin-based chemotherapy for small cell lung cancer are described. Carboplatin plus vincristine given with or without ifosfamide resulted in response rates of 36% and 53%, respectively, in so-called chemotherapy-resistant patients. Toxicity of the carboplatin/vincristine regimen was mild (hematologic toxicity grade 4 was seen with 13% of the courses), whereas the combination including ifosfamide resulted... Abstract
Cited 8 times since 1992 (0.2 per year) source: EuropePMC
European journal of cancer (Oxford, England : 1990), Volume 28, Issue 1, 1 1 1992, Pages 96-100 Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group. Postmus PE, Splinter TA, Palmen FM, Carney DN, Festen J, Burghouts JT, Vendrik C, Roozendaal K, Planting AS, Quoix E
The EORTC Lung Cancer Cooperative group performed a randomised phase II study in patients with small cell lung cancer comparing the standard cyclophosphamide/doxorubicin/etoposide (CDE) regimen with two regimens containing the new and active cisplatin derivative, carboplatin, 400 mg/m2 in combination with ifosfamide, a drug without important myelotoxicity, at a dose of 5 g/m2 (IMP) or the non-myelotoxic drug vincristine twice 2 mg (VP). Of 178 evaluable patients, 63 received CDE [30 limited dise... Abstract
Cited 5 times since 1992 (0.2 per year) source: EuropePMC
Chest, Volume 101, Issue 1, 1 1 1992, Pages 265-266 Fatal respiratory failure caused by pulmonary infiltration by pseudo-Gaucher cells. Links TP, Karrenbeld A, Steensma JT, Weits J, van der Jagt EJ, Postmus PE
Pseudo-Gaucher cells are reticuloendothelial cells that are found in several diseases. We report a case of pulmonary tuberculosis in which extensive pulmonary involvement with these cells resulted in fatal respiratory failure. Abstract
Cited 5 times since 1992 (0.2 per year) source: EuropePMC
European journal of cancer (Oxford, England : 1990), Volume 28A, Issue 12, 1 1 1992, Pages 1965-1967 Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer. Smit EF, Piers DA, Postmus PE
25 consecutive patients with advanced non-small cell lung cancer (NSCLC) were treated with high-dose epirubicin (HDE) 135 mg/m2 and etoposide 60 mg/m2 (days 1-3) every 3 weeks. 121 courses, (median 6, range 1-7), were administered and evaluable for toxicity: WHO grades III/IV leukocytopenia in 60/36 (80%) courses, thrombocytopenia in 18/6 (20%) and grades II/III anaemia in 31/6 (31%). Median (range) left ventricular ejection fraction (LVEF) fell from 63% (53-73, n = 25) to 60% (48-73 n = 16) aft... Abstract
Cited 1 times since 1991 (0 per year) source: EuropePMC
Chest, Volume 100, Issue 6, 1 1 1991, Pages 1685-1686 Consolidation of both upper lobes. van der Bij W, Gouw AS, Meinesz AF, van Ingen J, Postmus PE
The European respiratory journal, Volume 4, Issue 10, 1 1 1991, Pages 1307-1308 Progressive dysphagia. van der Graaf WT, Postmus PE
Cited 2 times since 1991 (0.1 per year) source: EuropePMC
Chest, Volume 100, Issue 5, 1 1 1991, Pages 1358-1363 Limitations of the fast green assay for chemosensitivity testing in human lung cancer. Smit EF, de Vries EG, Meijer C, Mulder NH, Postmus PE
Selection of patients with lung cancer who are most likely to benefit from chemotherapeutic treatment would be a substantial step forward. Therefore, a prospective study in predictive chemosensitivity testing in vitro using the fast green assay (FGA) as developed by Weisenthal et al was carried out. Sixty-six pretreatment tumor specimens were obtained, the majority by means of bronchoscopy (n = 42). Due to an initially insufficient yield of tumor cells (n = 19), dead cells in control samples aft... Abstract
Cited 6 times since 1991 (0.2 per year) source: EuropePMC
The European respiratory journal, Volume 4, Issue 4, 1 1 1991, Pages 503-504 Adult respiratory distress syndrome (ARDS) due to bacteraemic pneumococcal pneumonia. Mannes GP, Boersma WG, Baur CH, Postmus PE
We describe a patient, who had no pre-existing disease, with bacteraemic pneumococcal pneumonia and adult respiratory distress syndrome (ARDS), a rare complication. In spite of the use of antibiotics and intensive treatment the mortality rate of this kind of infection remains high. Streptococcus pneumoniae is the most frequently found micro-organism responsible for community-acquired pneumonia. In 25-35% of these patients pneumococcal bacteraemia is found, with a 2-3 times higher mortality rate... Abstract
Cited 10 times since 1991 (0.3 per year) source: EuropePMC
The European respiratory journal, Volume 4, Issue 2, 1 1 1991, Pages 243-245 Dyspnoea after pneumonectomy. Smeenk FW, Twisk SP, Berreklouw E, Gooszen HC, Postmus PE
We report the case of a 61 yr old male, who developed a severe right-to-left shunt through a patent foramen ovale, in the absence of elevated right-sided heart pressures, two months after a left-sided pneumonectomy. This is considered to be a rare complication after pneumonectomy. However, taking into account the approximately 20% incidence of patent foramen ovale in the general population, we suggest that right-to-left shunting through an unsuspected foramen ovale or atrial septum defect should... Abstract
Cited 2 times since 1991 (0.1 per year) source: EuropePMC
The European respiratory journal, Volume 4, Issue 2, 1 1 1991, Pages 232-234 Pericardial diverticulum with unusual symptomatology. Waterbolk TW, Henkens CA, Remmert DG, van der Jagt EJ, Postmus PE
A healthy 37 yr old female presented with recurrent right-sided chest pain which spontaneously disappeared. On a chest roentgenogram a lesion in the right cardiophrenic angle was found. Magnetic resonance imaging suggested a cystic structure. During thoracotomy a pericardial diverticulum was found. The pain was probably caused by intermittent volvulus of the diverticulum. Abstract
Cited 3 times since 1991 (0.1 per year) source: EuropePMC
The European respiratory journal, Volume 4, Issue 2, 1 1 1991, Pages 239-241 Late onset asthma? Aleva RM, Wouters B, Kraan J, Postmus PE
A 77 yr old male was referred for dyspnoea and recurrent infections of the lower airways for the previous five months. On the lateral chest roentgenogram a process in the tracheal area was found, and during bronchoscopy a polypoid tumour was seen about four centimetres above the main carina. It appeared to be a benign endotracheal tumour which was removed after coagulation by a Neodymium yttrium aluminium garnet (YAG) laser. Abstract
Cited 1 times since 1991 (0 per year) source: EuropePMC
Cancer chemotherapy and pharmacology, Volume 27, Issue 6, 1 1 1991, Pages 490-491 A feasibility study of testing new drugs for small-cell lung cancer in patients with a poor performance status. Postmus PE, Smit EF, Berendsen HH, Sleyfer DT
Testing of new drugs in small-cell lung cancer is definitely necessary for the development of agents that might be effective against this tumor. However, testing such drugs in previously untreated patients with a good performance status (PS) may give rise to ethical problems. When previously treated patients are used in testing, potentially effective agents could well elude discovery. Patients who are not eligible for "standard" combination chemotherapy, e.g. untreated patients with a... Abstract
Cited 16 times since 1991 (0.5 per year) source: EuropePMC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 9, Issue 1, 1 1 1991, Pages 100-110 Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study. Smit EF, Willemse PH, Sleijfer DT, Uges DR, Postmus PE, Meijer S, Terheggen PM, Mulder NH, de Vries EG
A phase I study with continuous infusion carboplatin for 21 days every 6 weeks using a venous access port and portable pump was performed over a dose range of 12 to 32 mg/m2/d, with increments of 2 mg/m2/d. Forty-four patients received 107 courses (median, two; range, one to nine). World Health Organization (WHO) grade III/IV leukopenia and thrombocytopenia occurred in one of seven patients at 30 mg/m2/d, and in two of six and four of six patients at 32 mg/m2/d. Cumulative platelet depression wa... Abstract
Cited 6 times since 1991 (0.2 per year) source: EuropePMC
The European respiratory journal, Volume 4, Issue 1, 1 1 1991, Pages 120-121 Mesothelioma presenting with pneumothorax and interlobar tumour. Mannes GP, Gouw AS, Berendsen HH, Verhoeff AJ, Postmus PE
A patient presented with a pneumothorax, a parahilar mass and a pleural effusion on the left side. Histology proved that this was caused by a malignant mesothelioma, epithelial type. The pneumothorax persisted, even after chest drainage and pleurodesis with talc powder and tetracycline. Abstract
Chest, Volume 99, Issue 1, 1 1 1991, Pages 209-210 Sudden superior mediastinal enlargement. Aalbers R, Piers B, Eygelaar A, Postmus PE
Cited 2 times since 1990 (0.1 per year) source: EuropePMC
The European respiratory journal, Volume 3, Issue 10, 1 1 1990, Pages 1224-1226 Bullous degeneration of the left lower lobe in a heroin addict. Smeenk FW, Serlie J, van der Jagt EJ, Postmus PE
A 34 yr old heroin addict was referred because of chest pain caused by air-trapping in a bulla in the left lower lobe. There was a marked difference between the functional residual capacity measured by body-plethysmography and helium dilution. A slow wash-in and wash-out were demonstrated by ventilation scintigraphy with Xenon133. Bullous degeneration is a known complication of intravenous drug abuse. Usually these bullae are found in the upper lobes. Possible causative mechanisms are discussed. Abstract
Cited 8 times since 1990 (0.2 per year) source: EuropePMC
The European respiratory journal, Volume 3, Issue 8, 1 1 1990, Pages 932-933 Amyloid tumour resected by laser therapy. Russchen GH, Wouters B, Meinesz AF, Janssen S, Postmus PE
We report a patient presenting with dyspnoea, cough and fever with a middle lobe atelectasis. Amyloid deposits in the bronchial wall caused almost complete obstruction of the middle lobe bronchus. The patient was treated with neodymium yttrium aluminium garnet (NdYAG) laser photoresection resulting in complete clearance of the middle lobe bronchus. Laser therapy has to be considered as first-line therapy for patients with endobronchial amyloidosis. Abstract